Veracyte Inc (FRA:12V)
€ 32 0.6 (1.91%) Market Cap: 2.54 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 2.37 GF Score: 83/100

Veracyte Inc at UBS Global Healthcare Conference Transcript

May 20, 2019 / 01:30PM GMT
Release Date Price: €21.8 (-1.80%)
Daniel Gregory Brennan
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences

Great. So welcome. First day of the UBS Global Healthcare Conference 2019. My name is Dan Brennan. I cover life science tools, diagnostics and pharma services. Pleased to be joined here on stage with the senior management team of Veracyte. To my left, Bonnie Anderson, Chairman and CEO; and to her left, Keith Kennedy, Chief Financial Officer.

Before we start, please go to www.ubs.com for all disclaimers. I think Bonnie and Keith are going to go through abbreviated presentation, given many of the investor base might be reasonably new to the story, then we'll go into Q&A.

And just as a precursor, my predecessor from eons ago, I was actually involved with taking Bonnie and Veracyte public, so I did a lot of diligence on the company back then. And certainly, for a company that couldn't get a 2 or 3x multiples, certainly things have gone well with you executing the strategy. So kudos to you. And with that,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot